Reuters
03 Sept 2026, 10:32 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
2 claims · each scored for market impact
Ultragenyx Pharmaceutical's late-stage trial for a neurodevelopmental disorder treatment failed. — The failure of a primary growth driver in a late-stage trial typically leads to massive valuation write-downs for biotech firms.
-0.90Ultragenyx shares plunged more than 40% in premarket trading. — This reflects immediate market repricing and a loss of investor confidence in the company's near-term pipeline.
-0.50Which stocks this story touches
Shares plummeted over 40% following the failure of a late-stage trial for a key growth treatment.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
12h ago
